Efficacy of Gabapentin in the Treatment of Chest Pain and Paresthesia in Patients With Sternotomy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00800527 |
Recruitment Status :
Completed
First Posted : December 2, 2008
Last Update Posted : December 2, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chest Pain Paresthesia | Drug: Gabapentin Drug: Diclofenac | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 110 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase 4 Study of Efficacy of Gabapentin in the Treatment of Chest Pain and Paresthesia in Patients With Sternotomy |
Study Start Date : | November 2007 |
Actual Primary Completion Date : | June 2008 |
Actual Study Completion Date : | October 2008 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1
Gabapentin
|
Drug: Gabapentin
Gabapentin 800 mg one a day up to 30 day
Other Name: Group-1: Gabapentin Arm |
Active Comparator: 2
Diclofenac
|
Drug: Diclofenac
Diclofenac 75 mg one a day up to 30 day
Other Name: Group-2: Diclofenac arm |
- Reduction of pain or paresthesia severity [ Time Frame: one month ]
- duration of relief of pain or paresthesia [ Time Frame: three month ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 85 Years (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Poststernotomy chest pain and/or paresthesia
Exclusion Criteria:
- Osteoporosis, renal function impairment (creatinine value >1.5 mg / dl.)
- Hepatic dysfunction, peptic ulcer, chest pain with ischemic origin, pediatric cases
- Over production of scar tissue, thoracic surgery other than sternotomy -
- Redo-bypass surgery, infection, sternal dehiscence,valve surgery together with bypass

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00800527
Turkey | |
Usak State Hospital | |
Usak, Turkey, 64100 |
Principal Investigator: | Ismail BIYIK, MD | Investigator |
Responsible Party: | Ismail BIYIK, Investigator |
ClinicalTrials.gov Identifier: | NCT00800527 |
Other Study ID Numbers: |
B4ISM4350015-009/295 |
First Posted: | December 2, 2008 Key Record Dates |
Last Update Posted: | December 2, 2008 |
Last Verified: | November 2008 |
sternotomy pain paresthesia Poststernotomy chest pain Poststernotomy chest paresthesia |
Paresthesia Chest Pain Pain Neurologic Manifestations Somatosensory Disorders Sensation Disorders Nervous System Diseases Diclofenac Gabapentin Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anticonvulsants Anti-Anxiety Agents |
Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Antimanic Agents Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Anti-Inflammatory Agents Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors |